Products and Resources Catalog

Talking To Change: A Motivational Interviewing Podcast, hosted by Glenn Hinds and Sebastian Kaplan, is a series of conversations exploring Motivational Interviewing (MI) and its influence on supporting individuals and groups as they make positive health and lifestyle changes, Talking to Change: An MI Podcast. Episode 42: MI for People with Opioid Use and Stimulant Use Disorders, with Roy Stein, MD In this episode (the first of two episodes about MI for opioid and stimulant use disorders), Glenn and Sebastian talk to Dr. Roy Stein, Clinical Professor of Psychiatry at University of North Carolina’s School of Medicine. Dr. Stein talks about ways to help people engaging in behavior that puts them at high risk for death, managing the “righting reflex” and reducing risk for burnout, the role of harm reduction for opioid use disorders, adaptations of MI for stimulant use disorders, medication treatment for substance use disorders, and more. Download transcript (pdf)

Talking To Change: A Motivational Interviewing Podcast, hosted by Glenn Hinds and Sebastian Kaplan, is a series of conversations exploring Motivational Interviewing (MI) and its influence on supporting individuals and groups as they make positive health and lifestyle changes. Talking to Change: An MI Podcast. Episode 44: MI and Social Support for Opioid and Stimulant Use Disorders, with Paul Delaney In part two of a pair of episodes on MI for opioid and stimulant use disorders, Glenn and Sebastian talked to Paul Delaney, clinical supervisor, therapist, adult educationalist, and trainer in Dublin, Ireland. Paul talked about working with people who misuse opioids and stimulants, how to avoid the premature focus trap, ways to support autonomy with someone who uses heroin, harm reduction, and MI and restorative justice.  Download the transcript (pdf)  

This training focuses on reducing personal, public, and institutionalized biases around people with substance use disorder. We will learn details of drug use, overdose, and navigating the care continuum by someone with lived experience who is now a Peer Recovery Support Specialist in Kansas City, MO. We will look at this story and the role bias played in delaying and distressing the recovery process. Participants learn about types of stigma, addiction on the brain, and evidence-based practices in overdose response. There will be multiple opportunities to observe how bias affects their own experiences and to discuss ways to shift attitudes and improve actions which lead to better outcomes and more people in recovery. Click here to watch the presentation!

This is the final session of the 3-part series Embracing Pregnant & Parenting Families Challenged with Substance Use Disorder. After the session, participants will be able to: Recognize data relevant to addiction and recovery in the United States Define stigma and examine its impact upon individuals experiencing addiction and those in recovery Discuss implicit bias and examine strategies to examine and reduce our own unconscious bias Illustrate the power of language in relationship to stigma and contrast stigmatizing language with the language of recovery Identify actions each member of the health care team can take to reduce the impact of stigma Click here to watch the presentation Presenter Information: Sharon Hesseltine, BSW, is President and CEO of Intentional Development, providing consultation, facilitation and training to strengthen services for pregnant and parenting families who have substance use disorders, adverse childhood experiences (ACEs) and trauma. For over 30 years Sharon has worked in Public Health and specialized in early childhood development, women’s health, substance use disorder and recovery.  

In this session, Larissa Mooney, MD, one of two PIs for the Greater Southern California Node of the NIDA Clinical Trials Network, discussed recent trends in co-occurring methamphetamine use and opioid use disorder (OUD), including overdose fatalities. Participants also learned about the treatment approaches to address this rising comorbidity. This webinar was sponsored by the Northwest and Pacific Southwest ATTCs and the Western States Node of the NIDA Clinical Trials Network. Download slides

  Participants in this webinar will be able to name ways addiction impacts the maternal and infant brain, identify prevention strategies, describe the significance of attachment parenting to promote infant resilience, and discuss the risk of inherited genetics. 

  Participants in this webinar will be able to name two brain systems impacted by exposure to adverse childhood experiences, describe three social, emotional, and behavioral impacts of exposure to ACEs during adolescence, and identify stigma in self and in others. 

This three-part series will focus on the principles of harm reduction and its strategies to advance holistic services for individuals with substance use disorder (SUDs). Research indicates that harm reduction programs are evidence-based public health strategies designed to prevent overdose deaths, infectious disease, sexually transmitted infections, pregnancies, and injection drug use. For example, expanding access to naloxone for individuals using opioids is considered a harm reduction strategy. Specifically, this webinar series will include: an overview of the principles of harm reduction and their application in a harm reduction center; the importance of engaging law enforcement especially in rural areas and co-responder models; and a panel of experts discussing their expertise in offering harm reduction strategies in their service delivery as well as a consumer of harm reduction services.   Session One March 30, 2021, from noon to 1:00 MT, will feature Lisa Raville, Executive Director of the Harm Reduction Action Center in Denver, CO. Ms. Raville will provide an overview of the principles of harm reduction.   The learning objectives include: -An examination of the principles and evidence for the application of harm reduction strategies. -The role of harm reduction programs in eliminating stigma and shame. -Strategies to work cross-systems to advance harm reduction. -Data from a recent survey of healthcare workers.   Video Link   Session Two April 13, 2021, from noon to 1:00 MT, will feature Chief Rick Brandt, Chief of Police in Evans, CO. Chief Brandt will provide content specific to engagement with law enforcement in harm reduction to include: -Strategies to educate law enforcement on harm reduction in rural communities. -Content on how to implement harm reduction in a PD and the leadership strategies employed. -The role of law enforcement in working cross-system to prevent overdose deaths. -Application of co-responder models. Video Link     Session Three April 27, 2021, from noon to 1:30 MT, will feature a panel discussion to include the following panelists: (1) Lisa Raville, Executive Director of the Harm Reduction Action Center in CO, (2) Chris Harsell, ATTC Technical Trainer and Medical Director for Spectra Health in ND, (3) Gabriela Zapata-Alma, Director of Policy and Practice on Domestic Violence and Substance Use for the National Center on Domestic Violence, Trauma, and Mental Health in Chicago, Il, (4) and a consumer of harm reduction services. The focus will be on: -Responding to questions surrounding implementation strategies. -Community and consumer benefits of harm reduction services. -How harm reduction can be employed in any agency. Video Link  

The Kansas City Perinatal Recovery Collaborative (KCPRC) was formed in June 2018 by Mid-America ATTC in response to the growing impact of substance use on families in the bi-state metropolitan area.  The KCPRC works to develop, grow, and nurture a coordinated, multi-system network of services and programs to support pregnant and parenting mothers as they navigate the dual journey of parenting and recovery. KCPRC is a collective of professionals from child development, child welfare, housing, social services, health care, criminal justice, and substance use disorder treatment and recovery.  The group focuses on evidence-based ways care can be improved from pregnancy and throughout a woman’s continuum of care. 

BHMEDS-R3 App The BHMEDS-R3 app is designed as a quick reference for non-prescriber behavioral health professionals and consumers who need general knowledge about medications prescribed for behavioral health conditions. The language has been modified to increase readability for a larger audience and, in keeping with the goal of continuously updating the app content, new medications are added after FDA approval. Download the FREE app using the QR codes below. Use the BHMEDS-R3 app for the following: Browse through different types of behavioral health medications Click a medication category icon to learn more details, including brand and generic names Use drop-down navigation menus to learn more about medications’ purpose, dose and frequency, side effects, emergency conditions, misuse potential, and cautions. Access provider tools and other free medication resources   BHMEDS-R3 Behavioral Health Medications Originally developed as a companion piece to the Mid-America ATTC curriculum, A Collaborative Response: Addressing the Needs of Consumers with Co-Occurring Substance Use and Mental Health Disorders (2000), this publication is now available as a downloadable PDF and replicates the content included in the new BHMEDS-R3 app now available in the Apple App Store and Google Play.  Back by popular demand, this 10th Edition publication is acclaimed for its accessibility as an educational reference for addiction professionals, patients, and families. Educators and addiction counselor training programs across the United States have asked that we continue to update and publish a downloadable publication to reflect the same credible and up-to-date information included in the BHMEDS-R3 app. We attempt to update the BHMEDS-R3 app content annually and publish an updated publication biannually.    Medications are organized in 11 sections: Alcohol Use Disorder Treatment Antianxiety Medications Antidepressant Medications Antimanic/Mood Stabilizer Medications Antipsychotics/Neuroleptics Hypnotics (Sleep Aids) Medications Induced Symptoms Treatment Narcotic and Opioid Medications Opioid Use Disorder Treatment Stimulant Medications Tobacco   Each section includes the following topics for the different medication types: Generic and Brand Name Medications: includes both approved FDA approved and “off label” medications.  Purpose: Describes typical uses of medications, including specific symptoms treated and positive treatment response expected.  Dose & Frequency: Discusses when and how medications are administered.  Side Effects: Discusses potential side effects, and methods for monitoring side effects.  Emergency Conditions: Includes risks associated with overdose, withdrawal or other medications’ reactions. Misuse Potential: Elaborates upon those medications with risk factors related to misuse and/or development of physical dependence.  Cautions: Describes general guidance on risks associated with taking medications    IMPORTANT NOTES ACROSS MEDICATION TYPES Name brand medications have a limited patent. When the patent expires, the medication may be made as a generic. The generic name of a medication is the actual name of the medication and never changes. A generic medication may be made by many different manufacturers and can make several forms of a single medication with only slight variations in color, size, or shape.  

This resource is designed to provide important talking points to use when meeting with or talking to tribal leaders, elders, community members, multi-disciplinary task force members, or local county workers about substance use disorders (SUD), medication assisted treatment (MAT), and other behavioral health issues. This electronic version is available on our website. We also have a print version. To request copies, please email us at [email protected]. 

This document is designed to reduce this information gap and help individuals and organizations better understand how the legal landscape in their state may impact access to harm reduction services and supplies, including overdose Good Samaritan laws, which provide limited protection from criminal sanctions to encourage people to call for help in an overdose emergency.

This webinar gives general information to help new TOR grantees get started implementing their grant. 

This optional TA tool is designed to assist Tribal Opioid Response (TOR) grantees that need assistance in developing an implementation plan to organize and guide their grant activities. This TA tool includes three parts: Practical instructions for completing an Implementation Plan A sample Implementation Plan (partially completed) A blank Implementation Plan template for use or adaptation

  Monthly e-newsletter of the Great Lakes ATTC, MHTTC, and PTTC. February 2021 issue features include Counselor's Corner article on the recovery legacies of Frederick Douglass and Malcom X, a state spotlight on Ohio, news about the new Peer Recovery Center of Excellence, and a calendar of upcoming trainings. 

Peer to peer consultation on Medication-Assisted Treatment (MAT) with Ted Hill, Ho Chunk Nation

Peer to peer consultation on Medication-Assisted Treatment (MAT) with Ted Hill, Ho Chunk Nation

Presenters: Rosalie Liccardo Pacula, PhD, and Rosanna Smart, PhD ABSTRACT: Numerous private and public agencies are collecting and reporting out information on state opioid policies to facilitate greater analysis and dissemination of state approaches for tackling the opioid epidemic. Most agencies focus on laws/statutes, which means that this is where the bulk of the research is happening. Definitions of many policies differ across some of the most commonly relied upon sources, which contributes to uncertainty regarding their impact. In this workshop, we will discuss some of the most common definitions being used for various policies, discuss how differences in assumptions regarding the meaning of “effective date” can have important implications regarding the likelihood of finding an impact through analysis, and discuss the importance of considering multiple policy domains.

Presenters: Megan Schuler, PhD, and Beth Ann Griffin, PhD ABSTRACT: Motivated by the context of opioid policy research, this workshop will provide an overview of key methodological challenges faced when evaluating the effectiveness of state-level policy using annual state- level data, as well as potential solutions and practice guidelines. We will begin discussing the commonly used linear difference-in-difference (DID) model and then subsequently discuss DID extensions and alternative approaches (i.e., autoregressive models, non-linear models, doubly robust methods, synthetic controls). Methods will be demonstrated in STATA using an opioid policy case study.

Objetivos: Repasar el uso y abuso de las sustancias ilegales durante el embarazo Presentar nuestro conocimiento la identificación y manejo de la Hepatitis C durante el embarazo Actualizar nuestro conocimiento con respecto a la pandemia del virus COVID 19 y su impacto en las mujeres embarazadas   Recursos Addicionales: Webinar slide handouts Not all vaccines are created equal Society for Maternal-Fetal Medicine (SMFM) Statement: SARS-CoV-2 Vaccination in Pregnancy Labor and Delivery COVID-19 Considerations WHO FAQ Website: Coronavirus disease (COVID-19): Vaccines   Presentador: Luis A. Izquierdo, M.D.

Happy December everyone! The holidays are here, and we wanted to share some words of encouragement to all of those who are striving for sober celebrations. #NHLATTC #NHLPTTC #Holidays #sobercelebrations #recoveryjourney #peersupport Disponible en Español ¡Feliz mes de diciembre a todos! Las fiestas están por comenzar, y queremos compartir algunas palabras de aliento a todos aquellos en recuperación que se esfuerzan por tener celebraciones libre de alcohol y drogas. #NHLATTC #NHLPTTC #Fiestas #celebracionessobrias #procesoderecuperación #apoyodecompañeros Disponible en Portugués Feliz dezembro à todos! As festas de final de ano estão chegando e gostaríamos de deixar algumas palavras de incentivo à todos aqueles em recuperação que estão se esforçando para ter celebrações sem álcool e drogas. #NHLATTC #NHLPTTC #Festas #sobercelebrations #recoveryjourney #peersupport

The fight against COVID-19 continues throughout the U.S., increasing stress and anguish among vulnerable populations struggling with substance use. Among those vulnerable populations, pregnant women present major concerns as they face an increase in adversity during the wake of the global pandemic. It is a difficult time for everyone, especially those facing more adversities such as pregnant women. Health providers and mental health providers must be highly vigilant in caring for pregnant women and should consider providing the following tools and resources, according to American Society of Addiction Medicine. Download the Substance Use and Pregnancy During COVID-19 factsheet for more information and resources. La lucha contra el COVID-19 continúa en los Estados Unidos, aumentando el estrés y la angustia entre poblaciones vulnerables que luchan contra el uso de sustancias. Entre esas poblaciones vulnerables, las mujeres embarazadas presentan grandes preocupaciones al enfrentar un aumento de adversidad durante el despertar de la pandemia global. Es un momento difícil para todos, especialmente aquellos que enfrentan más adversidades como las mujeres embarazadas. Los proveedores de salud y de salud mental deben estar muy atentos al cuidar a las mujeres embarazadas y deben considerar proporcionar las siguientes herramientas y recursos, según la Sociedad Americana de Medicina de la Adiccion.  Descargue la hoja informativa Uso de Sustancias y Embarazo Durante COVID-19 para obtener más información y recursos. A luta contra a COVID-19 ainda continua nos Estados Unidos, aumentando o estresse e a angústia entre as populações vulneráveis ​que lutam contra o uso de substâncias. Entre essas populações vulneráveis, as mulheres grávidas apresentam grandes preocupações porque elas enfrentam um aumento da adversidade durante o despertar de uma pandemia global. É um momento difícil para todos, especialmente para aqueles que enfrentam mais adversidades, como as mulheres grávidas. Provedores de saúde e profissionais de saúde mental devem estar altamente vigilantes ao cuidar de mulheres grávidas e devem considerar fornecer as seguintes ferramentas e recursos, de acordo com a Sociedade Americana de Dependência Química. Baixe o folheto informativo USO DE SUBSTÂNCIAS E A GRAVIDEZ DURANTE COVID-19 para obter mais informações e recursos.

Presenters: Elizabeth Needham Waddell, PhD; Morgan Nelson, CRM, CADC; Christi Hildebran, LMSW, CADC III; and Erin Stack, MS. October 6, 2020 Sponsored by the Northwest ATTC and the CTN Western States Node. Peer recovery support services are supports provided across the service continuum by credentialed individuals in long-term recovery from alcohol or other drug-related problems. Peer recovery support specialists serving people following release from jails and prisons have a unique responsibility to support community reentry and adherence to community corrections requirements. They may also facilitate entry into treatment post-release and support engagement in recovery services in the months following incarceration. This webinar described the unique role of peer support specialists in the CDC-funded pilot project Reducing Overdose After Release from Incarceration (ROAR). The ROAR pilot combines provision of medication for opioid use disorder with support from Oregon Certified Recovery Mentors (CRMs) to reduce overdose risk among women released from prison. Download slides | ROAR Project protocol | Watch recording

Addressing Stigma and Substance Use Disorders: A HealtheKnowledge Course DESCRIPTION This course is designed to serve a broad audience including: health care and behavioral health administrators and supervisors; direct care providers of behavioral health service; and students in pre-service classes. This course provides content valuable for myriad professionals to consider in their day-to-day work when serving people with substance use disorders. The topics selected will allow participants to gain a deeper understanding of the nature and context of stigma. The four-hour course includes five 45-minute video modules on topics related to stigma in the SUD field. There is a quiz after each module. Once you have completed the 5 modules and passed the quizzes with a score of 80% or better, you will be able to access a certificate of course completion. This course represents 4.0 continuing education hours or credits, which are available from NAADAC.        Module 1: Stigma of Substance Use Disorders: An Overview Module 2: Addressing SUD & Structural Stigma: Opportunities & Challenges Module 3: Stigmata - Stigma of Medications for Opioid Use Disorder Module 4: The Stigma is Real: Pregnant and Parenting Women with Substance Use Disorders Module 5: Stigma and Substance Use Disorders: A Historical Walk   Click Here to Register